Publications by authors named "Wen Yu Zhai"

Background: We aimed to investigate the predictive value of a systematic serum inflammation index, pan-immune-inflammatory value (PIV), in pathological complete response (pCR) of patients treated with neoadjuvant immunotherapy to further promote ideal patients' selection.

Methods: The clinicopathological and baseline laboratory information of 128 NSCLC patients receiving neoadjuvant immunochemotherapy between October 2019 and April 2022 were retrospectively reviewed. We performed least absolute shrinkage and selection operator (LASSO) algorithm to screen candidate serum biomarkers for predicting pCR, which further entered the multivariate logistic regression model to determine final biomarkers.

View Article and Find Full Text PDF

Background: Ground glass opacity (GGO) is associated with favorable survival in lung cancer. However, the relevant evidence of the difference in prognostic factors between GGO and pure-solid nodules for pathological stage I invasive adenocarcinoma (IAC) is limited. We aimed to identify the impact of GGO on survival and find prognostic factor for part-GGO and pure-solid patients.

View Article and Find Full Text PDF

The good pathological response of primary tumors (PTs) to neoadjuvant immunotherapy has been acknowledged in non-small cell lung cancer (NSCLC), however, it remains unclear whether neoadjuvant immunotherapy shows consistent effects in metastatic lymph nodes (LNs). We compared the pathological response of PT and nodal downstaging using a pooled analysis to assess the effect of neoadjuvant immunotherapy on LNs. Original articles reporting the tumor major pathological response (ypT(MPR)), pathological complete response (ypT0) and nodal downstaging following neoadjuvant immunotherapy in NSCLC were retrieved.

View Article and Find Full Text PDF

Costimulatory molecules are an indispensable signal for activating immune cells. However, the features of many costimulatory molecule genes (CMGs) in lung adenocarcinoma (LUAD) are poorly understood. This study systematically explored expression patterns of CMGs in the tumor immune microenvironment (TIME) status of patients with LUAD.

View Article and Find Full Text PDF

Aging is an inevitable process characterized by a decline in many physiological activities, and has been known as a significant risk factor for many kinds of malignancies, but there are few studies about aging-related genes (ARGs) in lung squamous carcinoma (LUSC). We designed this study to explore the prognostic value of ARGs and establish an ARG-based prognosis signature for LUSC patients. RNA-sequencing and corresponding clinicopathological data of patients with LUSC were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO).

View Article and Find Full Text PDF

Inflammation is an important hallmark of cancer and plays a role in both neogenesis and tumor development. Despite this, inflammatory-related genes (IRGs) remain to be poorly studied in lung adenocarcinoma (LUAD). We aim to explore the prognostic value of IRGs for LUAD and construct an IRG-based prognosis signature.

View Article and Find Full Text PDF
Article Synopsis
  • - Multimodal treatment, including a PD-1 inhibitor (toripalimab) and chemotherapy, shows potential in improving survival for patients with stage III non-small-cell lung cancer (NSCLC) by preoperative immunotherapy.
  • - In a phase 2 trial with 33 patients, 90.9% underwent surgery, and the major pathological response (MPR) rate was 60.6%, indicating good effectiveness of the treatment protocol before surgery.
  • - Surgical complications were generally manageable, with anemia being the most common serious side effect; overall, the combination therapy led to high MPR rates and successful surgeries for advanced NSCLC.
View Article and Find Full Text PDF

Background: The optimal treatment modality for patients with stage IA (T1N0M0) small-cell lung cancer (SCLC) is still unclear.

Methods: Patients who received surgical resection or chemo-radiotherapy (CRT) between January 2004 and December 2014 were identified from The Surveillance, Epidemiology and End Results (SEER) database. Surgical resection included lobectomy, wedge resection, segmentectomy with lymphadenectomy [examined lymph node (ELN) ≥1].

View Article and Find Full Text PDF

Background: The impact of the number of examined lymph nodes (ELNs) on stage correction and prognostication in patients with esophageal squamous cell carcinoma (ESCC) who underwent right transthoracic esophagectomy is still unclear.

Methods: Patients with ESCC who underwent right transthoracic esophagectomy at Sun Yat-sen University Cancer Center between January 1997 and December 2013 were retrospectively enrolled. The Cox proportional hazards regression model was used to determine the effect of ELN count on overall survival.

View Article and Find Full Text PDF

Background: Lobectomy has long been regarded as the standard treatment for operable non-small cell lung cancer (NSCLC). Recent studies suggested that segmentectomy could achieve a good prognosis for early-stage NSCLC and might be an alternative to lobectomy in this cohort. Until now, on the issue of comparison between lobectomy and segmentectomy, there remains no published randomized controlled trial (RCT), and all existing evidence is low.

View Article and Find Full Text PDF

Background: The impact of the number of examined lymph nodes (ELNs) on stage correction and prognostication in patients with oesophageal squamous cell carcinoma (ESCC) who underwent left transthoracic oesophagectomy is still unclear.

Methods: Patients with ESCC who underwent left transthoracic oesophagectomy at Sun Yat-sen University Cancer Center between January 1997 and December 2013 were retrospectively enrolled. The Cox proportional hazards regression model was used to determine the effect of ELN count on overall survival (OS).

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Wen Yu Zhai"

  • - Wen Yu Zhai's recent research focuses on advancing the understanding and treatment of lung cancer, particularly through the integration of innovative predictive markers such as the pan-immune-inflammatory value (PIV) for assessing patient responses to immunotherapy in non-small-cell lung cancer (NSCLC).
  • - Zhai investigates the prognostic factors tied to different lesion characteristics in lung adenocarcinoma, revealing significant differences between ground glass opacities and pure-solid lesions which could influence patient management decisions.
  • - The author has also developed novel diagnostic models using bioinformatics and machine learning to predict immune microenvironment statuses in lung adenocarcinoma, alongside exploring aging-related gene signatures that could enhance prognostic assessments in lung squamous carcinoma, indicating a comprehensive approach to tailored cancer therapies.